Phase 1 Trial of the Safety and Immunogenicity of PENNVAX ® -G DNA Prime Administered by Biojector ® 2000 or CELLECTRA ® EP Device with MVA-CMDR Boost von Ake, Julie, Ratto-Kim, Silvia, Schuetz, Alexandra, Wieczorek, Lindsay, Nguay, Viseth, Kibuuka, Hannah, Sawe, Fredrick, Maboko, Leonard, Polonis, Victoria, Weiner, David, DeSouza, Mark, Sekiziyivu, Arthur, Kosgei, Josphat, Missanga, Marco, Kroidl, Arne, Earl, Patricia, Moss, Bernard, Adams, Elizabeth, Martinez, Ana, Rizvi, Farrukh, Khan, Amir, Sardesai, Niranjan, Michael, Nelson, Marovich, Mary, Robb, Merlin

Volltext